New Emerging Stem Cell Index - Mike Havrilla

Sign Up | Log In | What is SocialPicks?

New Emerging Stem Cell Index
Feb 02, 2009 12:10 PM UTC

Mike Havrilla

Return	Risk
+1.04%	LOW

Principal

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
ISCO	n/a
CUR	n/a
BMTI	n/a
OPXA	n/a
CCYGE	n/a
RGN	n/a
OSTE	n/a
LSTM	n/a
ASTM	n/a
CYTX	n/a
GERN	n/a
MCET	n/a
SCII	n/a
SCAL	n/a
SCLL	n/a
KOOL	n/a
PSTI	n/a
RTIX	n/a
OSIR	n/a
CBAI	n/a
ATHX	n/a
BCLI	n/a
BHRT	n/a
NBS	n/a
STEM	n/a
ACTC	n/a

Via ETF Innovators, LLP:

Shares of Geron (GERN) and other well known stem cell and regenerative medicine stocks such as Osiris Therapeutics (OSIR) and StemCells (STEM) have been soaring since the FDA allowed human clinical testing for Geron's embryonic stem cell treatment candidate for spinal cord injuries.

The accompanying table (click to enlarge) highlights 25 U.S.-listed stem cell and regenerative medicine companies with market caps of below $200M which are included in the ETF Innovators Emerging Stem Cell Index. The companies are also listed below in descending order by market cap.

BioMimetic Therapeutics (BMTI)
Cytori Therapeutics (CYTX)
RTI Biologics (RTIX)
Aastrom Biosciences (ASTM)
Mesoblast (MBLTY)
Neuralstem (CUR)
Osteotech (OSTE)
ThermoGenesis (KOOL)
RegeneRx Biopharma (RGN)
Advanced Cell Tecchology (ACTC)
Pluristem Therapeutics (PSTI)
Athersys (ATHX)
International Stem Cell Corp (ISCO)
Stem Cell Innovations (SCLL)
Bioheart (BHRT)
CellCyte Genetics Corp (CCYG)
Stem Cell Therapeutics (SCTPF)
Brainstorm Cell Therapeutics (BCLI)
Opexa Therapeutics (OPXA)
Stem Cell Authority (SCAL)
Neostem (NBS)
Stem Cell Therapy Internt'l (SCII)
Cord Blood America (CBAI)
MultiCell Technologies (MCET)
LifeStem International (LSTM)

While regenerative medicine holds enormous potential for breakthrough medical treatments, investors and traders should be cautious as the entire space is an extreme momentum trade since the FDA news to allow human testing of embryonic stem cells. President Obama is also expected to lift the federal ban under the previous administration to allow federal funding of stem cell research, providing another boon to these companies.

Click here for my previous articles on stem cell investing, including my favorite two companies from this index â€“ Cytori Therapeutics and ThermoGenesis, which are developing therapeutic and stem cell banking applications derived from a patient's own fat tissue and blood or bone marrow, respectively. Both of these companies already have products on the market, in addition to ongoing clinical studies for therapeutic applications of their stem cell and regenerative medicine systems and technology platforms.

Read the rest of original post »

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.